- Tivozanib for RCC
- Genitourinary Oncology: A Peek Over the ...
- Immunotherapy of Renal Cell Carcinoma
- Targeted Therapies for Renal Cell Carcinoma
- Genetics and Heterogeneity
- Genetic Predisposition to Kidney Cancers
- Personalized Medicines for Kidney Cancers
- Drugs in the Pipeline
- Resistance to Therapy Among Kidney Cancers
- Targeted Therapy
- The Role of Neoadjuvant Tx
- Sx Options – Ablative Techniques
- Sx Options – Lymph Node
- Sx Options – Cytoreductive Nephrectomy
- TKIs - First-Line Therapy
- TKIs – Second-Line Therapy
- Biomarkers in RCC
- The MET Pathway
- Checkpoint Inhibitors
Renal Cell Carcinoma News
Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma
More Renal Cell Carcinoma Information
An overview of the potential immune-related adverse events that can arise from treatment with checkpoint inhibitors.
Both the chemotherapy regimen selected and therapeutic dose intensity used in treatment factor into the calculation of neutropenia risk.
Traditional genetic testing historically included the sequential analysis of single and generally well-described genes involved in heritable cancers.
Some data suggest that psychotherapy may benefit patients with cancer, but higher-quality research is needed.
The effect of polypharmacy and noncancer mortality on patient survival and other outcomes in cancer varies by study.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer
- Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL